Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00442533
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Overview
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Sponsor
Unknown Organization
Phase
Phase 2/3
Contacts
Ebrahim Delpassand, M.D. (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT00442533Drug / Compound
Pentetreotide
Isotope(s):
INDIUM-111
Radioisotope: In-111
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 2.8 Days
Decay Mode: ELECTRON CAPTURE, GAMMA
Energy: 173 keV, 247 keV
Range: N/A
Decay Daughters: Cd111 (Stable)
Status: FDA Approvals: ONCOSCINT® (1992), OCTREOSCAN® (1994)
Target(s):
- SSTR2
Ligand Class: Peptides
Chelator: DTPA
Eligibility
Inclusion
- Patients must be greater than 18 years of age.
- All patients must have a Karnofsky performance status of at least 60.
- All patients must sign an informed consent indicating the awareness of the investigational nature of the studies involved.
- Patients must have evidence of residual multifocal active tumor.
- * Patients must have received first line standard chemotherapy and/or radiation therapy for neuroendocrine malignancy in the past and failed the therapy.
Exclusion
- Patients under 18 years of age. There will be no upper age discrimination.
- Patients with renal insufficiency as defined by a calculated creatinine clearance (based on age, weight and serum creatinine) of 39.9 ml/min or less.
- Patients who are pregnant or those potentially pregnant subjects not willing to practice effective contraceptive techniques during the study period.
- * Karnofsky performance status of 50 or less.
- Patients who are unable to give informed consent.
Share your feedback
Help us improve your experience